Media stories about DURECT (NASDAQ:DRRX) have trended somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DURECT earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 47.1829789177109 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of DURECT (NASDAQ:DRRX) traded up $0.04 during mid-day trading on Monday, reaching $0.96. 169,500 shares of the company’s stock traded hands, compared to its average volume of 354,550. The company has a market capitalization of $142.23, a price-to-earnings ratio of -6.40 and a beta of 1.69. The company has a current ratio of 1.67, a quick ratio of 1.57 and a debt-to-equity ratio of 1.46. DURECT has a twelve month low of $0.74 and a twelve month high of $2.17.

DURECT (NASDAQ:DRRX) last announced its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.09. The business had revenue of $20.75 million for the quarter, compared to analyst estimates of $5.09 million. DURECT had a negative net margin of 62.57% and a negative return on equity of 419.65%. analysts expect that DURECT will post -0.14 earnings per share for the current year.

Several analysts have commented on the stock. Stifel Nicolaus lowered shares of DURECT from a “buy” rating to a “hold” rating in a research report on Friday, October 20th. HC Wainwright reaffirmed a “hold” rating on shares of DURECT in a research report on Thursday, November 2nd. ValuEngine raised shares of DURECT from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. Finally, Laidlaw lowered their price objective on shares of DURECT from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Friday, October 20th.

TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/08/durect-drrx-earning-somewhat-favorable-news-coverage-study-shows.html.

About DURECT

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Insider Buying and Selling by Quarter for DURECT (NASDAQ:DRRX)

Receive News & Stock Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related stocks with our FREE daily email newsletter.